Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

VTRS

Viatris Inc

Apr 16 • 11:02AM ET

11.11

Dollar change -0.20
Percentage change -1.81	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO COWZ IVV VTV VOE RSP VYM GSLC

Scroll to Statements

Index	S&P 500	P/E	262.15	EPS (ttm)	0.04	Insider Own	2.01%	Shs Outstand	1.20B	Perf Week	-5.96%
Market Cap	13.20B	Forward P/E	3.97	EPS next Y	2.80	Insider Trans	-1.43%	Shs Float	1.16B	Perf Month	-6.91%
Income	54.70M	PEG	-	EPS next Q	0.68	Inst Own	80.86%	Short Float	3.13%	Perf Quarter	-5.40%
Sales	15.38B	P/S	0.86	EPS this Y	-5.31%	Inst Trans	2.13%	Short Ratio	3.98	Perf Half Y	19.13%
Book/sh	17.05	P/B	0.65	EPS next Y	0.65%	ROA	0.11%	Short Interest	36.39M	Perf Year	12.61%
Cash/sh	0.91	P/C	12.22	EPS next 5Y	-2.25%	ROE	0.26%	52W Range	8.74 - 13.62	Perf YTD	2.63%
Dividend Est.	0.51 (4.62%)	P/FCF	5.45	EPS past 5Y	-41.87%	ROI	0.15%	52W High	-18.38%	Beta	1.14
Dividend TTM	0.48 (4.32%)	Quick Ratio	1.13	Sales past 5Y	7.93%	Gross Margin	42.68%	52W Low	27.17%	ATR (14)	0.27
Dividend Ex-Date	Mar 08, 2024	Current Ratio	1.57	EPS Y/Y TTM	-97.35%	Oper. Margin	13.50%	RSI (14)	29.87	Volatility	2.20% 2.15%
Employees	38000	Debt/Eq	0.90	Sales Y/Y TTM	-4.90%	Profit Margin	0.36%	Recom	3.10	Target Price	12.50
Option/Short	Yes / Yes	LT Debt/Eq	0.80	EPS Q/Q	-177.06%	Payout	1059.60%	Rel Volume	0.51	Prev Close	11.32
Sales Surprise	-1.27%	EPS Surprise	-4.05%	Sales Q/Q	-0.95%	Earnings	Feb 28 BMO	Avg Volume	9.13M	Price	11.11
SMA20	-5.61%	SMA50	-8.33%	SMA200	3.74%	Trades		Volume	1,284,393	Change	-1.81%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold
Dec-14-20	Initiated	Bernstein	Mkt Perform	$21

Show Previous Ratings

Apr-15-24 08:00AM	Viatris Appoints Corinne Le Goff as Chief Commercial Officer (PR Newswire)
06:59AM	Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada (PR Newswire)
Apr-04-24 06:52AM	UPDATE 1-UK watchdog says Theramex-Viatris deal raises competition concerns (Reuters)
06:22AM	UK watchdog says Theramex-Viatris deal raises competition concerns (Reuters)
Apr-01-24 02:01PM	UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent (Reuters)
11:52AM	Loading…
11:52AM	Teva, Viatris win new chance to challenge J&J schizophrenia drug patent (Reuters)
07:14AM	Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris (GlobeNewswire)
06:59AM	Viatris Announces the Launch of RYZUMVl (Phentolamine Ophthalmic Solution) 0.75% in the United States (PR Newswire)
Mar-29-24 11:30AM	Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report? (Zacks)
Mar-27-24 06:59AM	Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline (PR Newswire)
Mar-18-24 02:00AM	Idorsia and Viatris successfully close the transaction for the global research and development collaboration (GlobeNewswire)
Mar-15-24 12:00PM	11 Undervalued Stocks for Less Than $50 in March 2024 (Investopedia)
Mar-14-24 09:53AM	Is Viatris a Great Dividend Stock or Just a Value Trap? (Motley Fool)
Mar-11-24 09:45AM	2 Dirt Cheap Dividend Stocks to Buy and Hold (Motley Fool)
07:24AM	UPDATE 2-US FDA declines to approve Viatris's injection for multiple sclerosis (Reuters)
07:06AM	Loading…
07:06AM	US FDA declines to approve Viatris's injection for multiple sclerosis (Reuters)
Mar-08-24 05:04AM	Viatris Inc's Dividend Analysis (GuruFocus.com)
Mar-07-24 08:49AM	Greenlight Capital Re, Ltd. (NASDAQ:GLRE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 11:52PM	Insider Sell: President of Greater China Xiangyang Ni Sells 21,532 Shares of Viatris Inc (VTRS) (GuruFocus.com)
10:38AM	Viatris Inc. (NASDAQ:VTRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:56AM	13 Best Pharma Dividend Stocks To Buy in 2024 (Insider Monkey)
Mar-04-24 11:24AM	Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise (Zacks)
Feb-28-24 10:43PM	Q4 2023 Viatris Inc Earnings Call (Thomson Reuters StreetEvents) -7.11%
07:01PM	Analyst Report: Viatris Inc. (Morningstar Research)
09:50AM	Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates (Zacks)
09:30AM	Viatris (VTRS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:19AM	Viatris forecasts strong 2024 sales on higher demand for branded drugs (Reuters)
07:52AM	Viatris Inc (VTRS) Meets 2023 Financial Targets and Sets Course for Continued Growth in 2024 (GuruFocus.com)
07:47AM	Idorsia, weeks from cash-tastrophe, bags $350M upfront from Viatris for 2 late-phase assets (FierceBiotech.com)
07:15AM	Viatris Guides FY24 In Line With Estimates - Update (RTT News)
06:41AM	Loading…
06:41AM	Viatris: Q4 Earnings Snapshot (Associated Press Finance)
06:34AM	Viatris pays $350M to gain two drugs from Idorsia (BioPharma Dive)
06:30AM	Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance (PR Newswire)
01:00AM	Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration (PR Newswire)
01:00AM	Idorsia and Viatris enter into a significant global research and development collaboration (GlobeNewswire)
Feb-23-24 11:54AM	Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store? (Zacks)
09:15AM	Insights Into Viatris (VTRS) Q4: Wall Street Projections for Key Metrics (Zacks)
Feb-12-24 07:04AM	Chris Davis Reduces Stake in Viatris Inc (GuruFocus.com)
Feb-05-24 06:59AM	Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Jan-25-24 04:44AM	Here's Why Greenlight Decided to Repurchase Viatris (VTRS) (Insider Monkey)
Jan-22-24 11:02AM	12 S&P 500 Stocks On the Move (Insider Monkey)
Jan-16-24 08:17AM	These 9 Stocks Are Running To Start 2024 (Investor's Business Daily)
Dec-28-23 07:13PM	Analyst Report: Viatris Inc. (Morningstar Research)
Dec-27-23 04:33PM	Regeneron Gains After Eye-Drug Patent Victory Over Viatris (Bloomberg)
Dec-21-23 04:05PM	Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-15-23 05:13PM	UPDATE 1-Drugmaker Viatris appoints Theodora Mistras as CFO (Reuters)
04:55PM	Viatris appoints Theodora Mistras as CFO (Reuters)
04:45PM	Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora 'Doretta' Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer (PR Newswire)
04:05PM	Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders (PR Newswire)
Dec-11-23 04:37PM	15 Best Undervalued Stocks To Buy Now According To The Media (Insider Monkey)
Dec-07-23 11:31AM	Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-30-23 07:30AM	Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024 (InvestorPlace)
Nov-24-23 08:16PM	Insider Sell Alert: President, Greater China Xiangyang Ni Sells 14,937 Shares of Viatris Inc (VTRS) (GuruFocus.com)
Nov-22-23 06:38AM	Viatris partnered ulcerative colitis drug fails interim phase 3 review, sending InDex's stock down 60% (FierceBiotech.com)
Nov-21-23 06:00PM	Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care (ACCESSWIRE)
05:09AM	Viatris Inc's Dividend Analysis (GuruFocus.com)
Nov-20-23 06:30AM	7 Low P/E Stocks Poised to Rebound (InvestorPlace)
Nov-17-23 03:00PM	Top 30 Lowest P/E Ratios of the S&P 500 (Insider Monkey)
11:32AM	Why the Cheapest Stock in the S&P 500 Is No Bargain (Barrons.com)
Nov-14-23 08:00AM	Viatris to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-13-23 08:00AM	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
Nov-10-23 09:30AM	Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
Nov-09-23 03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
12:18AM	The Viatris Inc (VTRS) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 03:36PM	Viatris Inc. (NASDAQ:VTRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:17PM	Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip (Zacks)
10:34AM	Analyst Report: Viatris Inc. (Morningstar Research)
Nov-07-23 05:25PM	Viatris (VTRS) Beats Q3 Earnings Estimates (Zacks)
04:27PM	Viatris: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] (PR Newswire)
Nov-06-23 10:47AM	Should You Buy Viatris (VTRS) Ahead of Earnings? (Zacks)
Nov-05-23 01:27AM	Is Viatris (VTRS) a Smart Long-Term Pick? (Insider Monkey)
Oct-31-23 11:17AM	Viatris (VTRS) to Report Q3 Earnings: Is a Beat in Store? (Zacks)
10:01AM	Viatris (VTRS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
05:05AM	Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors? (Motley Fool)
Oct-30-23 04:35PM	13 Most Undervalued Pharma Stocks To Buy According To Analysts (Insider Monkey)
04:30PM	Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance (ACCESSWIRE)
12:10PM	Why Viatris (VTRS) is Poised to Beat Earnings Estimates Again (Zacks)
09:00AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Oct-29-23 05:35PM	14 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds (Insider Monkey)
Oct-27-23 08:45AM	Viatris Named to 3BLs 100 Best Corporate Citizens of 2023 Ranking (ACCESSWIRE)
Oct-25-23 04:00PM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row (ACCESSWIRE)
Oct-24-23 02:44PM	Bill Miller Portfolio: 12 Picks From Legendary Value Investor (Insider Monkey)
11:02AM	12 Defensive Healthcare Dividend Stocks To Invest In (Insider Monkey)
Oct-23-23 12:52PM	Markets Turn Positive at Midday After 10-Year Treasury Yield Reverses Course (Investopedia)
09:00AM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row (PR Newswire)
Oct-20-23 05:00PM	Rajiv Malik to Retire as President of Viatris Effective April 1, 2024 (PR Newswire)
Oct-18-23 08:00AM	Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking (PR Newswire)
Oct-13-23 09:15AM	Viatris Just Sold Off 3 Key Segments. Is It Still a Buy? (Motley Fool)
Oct-10-23 09:29AM	Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023 (PR Newswire)
Oct-08-23 09:45AM	2 Top Value Stocks to Buy in October (Motley Fool)
08:15AM	2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip (Motley Fool)
Oct-03-23 12:28PM	Viatris (VTRS) to Divest Some More Businesses, Shares Gain (Zacks)
Oct-02-23 04:54PM	US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic (Reuters)
04:31PM	Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion (Investor's Business Daily)
03:58PM	Analyst Report: Viatris Inc. (Morningstar Research)
11:33AM	Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Oct-01-23 06:01PM	UPDATE 2-Drugmaker Viatris to divest some businesses for $3.6 bln (Reuters)
05:16PM	Drugmaker Viatris to divest some of its businesses (Reuters)
05:00PM	Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA (PR Newswire)

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mauro Anthony	See Remarks	Mar 13 '24	Sale	12.09	250,000	3,023,700	243,044	Mar 15 06:00 PM
Campbell Paul	See Remarks	Mar 05 '24	Sale	12.33	24,353	300,272	153,826	Mar 05 08:36 PM
Lyons Dillon JoEllen	Director	Mar 05 '24	Sale	12.36	20,000	247,200	58,714	Mar 05 08:19 PM
Cuneo Andrew	See Remarks	Mar 04 '24	Option Exercise	0.00	6,838	0	62,542	Mar 05 07:47 PM
Malik Rajiv	President	Mar 04 '24	Option Exercise	0.00	89,514	0	1,027,249	Mar 05 08:09 PM
Campbell Paul	See Remarks	Mar 04 '24	Option Exercise	0.00	19,427	0	185,132	Mar 05 08:36 PM
Mauro Anthony	See Remarks	Mar 04 '24	Option Exercise	0.00	39,784	0	507,164	Mar 05 08:35 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 04 '24	Option Exercise	0.00	8,222	0	112,336	Mar 05 08:09 PM
Roman Brian	Global General Counsel	Mar 04 '24	Option Exercise	0.00	18,650	0	163,817	Mar 05 08:29 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 04 '24	Sale	12.51	21,532	269,314	90,804	Mar 05 08:09 PM
Mauro Anthony	See Remarks	Mar 03 '24	Option Exercise	0.00	37,835	0	485,243	Mar 05 08:35 PM
Campbell Paul	See Remarks	Mar 03 '24	Option Exercise	0.00	18,560	0	174,518	Mar 05 08:36 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '24	Option Exercise	0.00	140,727	0	135,829	Mar 05 08:01 PM
Malik Rajiv	President	Mar 03 '24	Option Exercise	0.00	85,788	0	978,180	Mar 05 08:09 PM
Lyons Dillon JoEllen	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	78,714	Mar 05 08:19 PM
Cuneo Andrew	See Remarks	Mar 03 '24	Option Exercise	0.00	13,199	0	61,485	Mar 05 07:47 PM
CORNWELL W DON	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	61,365	Mar 05 08:29 PM
Roman Brian	Global General Counsel	Mar 03 '24	Option Exercise	0.00	17,598	0	153,541	Mar 05 08:29 PM
FINNEY ELISHA W	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	18,855	Mar 05 08:25 PM
Groothuis Leo Frans	Director	Mar 03 '24	Option Exercise	0.00	22,484	0	22,154	Mar 05 08:24 PM
KILTS JAMES M	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	117,445	Mar 05 08:22 PM
KORMAN HARRY	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	89,806	Mar 05 08:23 PM
PARRISH MARK W	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	121,418	Mar 05 08:17 PM
MARK RICHARD A	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	72,333	Mar 05 08:14 PM
HIGGINS MELINA E	Director	Mar 03 '24	Option Exercise	0.00	18,855	0	102,236	Mar 05 08:13 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 03 '24	Option Exercise	0.00	14,298	0	104,114	Mar 05 08:09 PM
Ni Xiangyang (Sean)	President, Greater China	Mar 02 '24	Option Exercise	0.00	25,158	0	89,816	Mar 05 08:09 PM
Roman Brian	Global General Counsel	Mar 02 '24	Option Exercise	0.00	84,277	0	158,905	Mar 05 08:29 PM
Cuneo Andrew	See Remarks	Mar 02 '24	Option Exercise	0.00	25,692	0	52,167	Mar 05 07:47 PM
Malik Rajiv	President	Mar 02 '24	Option Exercise	0.00	433,416	0	1,008,849	Mar 05 08:09 PM
Campbell Paul	See Remarks	Mar 02 '24	Option Exercise	0.00	90,297	0	180,524	Mar 05 08:36 PM
Mauro Anthony	See Remarks	Mar 02 '24	Option Exercise	0.00	192,630	0	499,154	Mar 05 08:35 PM
Cuneo Andrew	See Remarks	Feb 23 '24	Sale	13.50	4,000	54,000	34,795	Feb 23 06:00 PM
Cuneo Andrew	See Remarks	Feb 15 '24	Sale	12.50	4,000	50,000	38,795	Feb 16 06:00 PM
Cuneo Andrew	See Remarks	Jan 04 '24	Sale	11.50	4,000	46,000	42,795	Jan 05 06:00 PM
Cuneo Andrew	See Remarks	Dec 14 '23	Sale	10.50	4,000	42,000	46,795	Dec 15 06:00 PM
Ni Xiangyang (Sean)	President, Greater China	Nov 24 '23	Sale	9.37	14,937	139,942	64,658	Nov 24 06:00 PM
Ni Xiangyang (Sean)	President, Greater China	Nov 23 '23	Option Exercise	0.00	33,179	0	79,595	Nov 24 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTRS

Viatris Inc

Upgrade your FINVIZ experience